We are live on ! Find out more
ARRY icon

Array Biopharma
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

191 hedge funds and large institutions have $2.56B invested in Array Biopharma in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 75 increasing their positions, 56 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $44M | Put options by funds: $22.5M

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

34% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 56

18% more capital inflows, than outflows

Capital inflows: $268M | Capital outflows: $228M

4% more funds holding

Funds holding: 184 → 191 (+7)

1.62% more ownership

Funds ownership: 99.98% → 101.6% (+1.6%)

4% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 27

Holders
191
Holders Change
+7
Holders Change %
+3.8%
% of All Funds
4.32%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.16%
New
26
Increased
75
Reduced
56
Closed
27
Calls
$44​M
Puts
$22.5​M
Net Calls
+$21.5​M
Net Calls Change
+$20.1​M

ARRY Hedge Fund Activity: Q4 2017 in Review

191 of the 4,418 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma (ARRY) for Q4 2017, worth a combined $2.56B — up 6.4% from $2.41B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of ARRY and 26 opened new positions — a net loss of 1 holder — while 56 trimmed existing stakes and 75 added.

The largest buyer was BVF Inc, adding an estimated $26M. The largest seller was OrbiMed, cutting an estimated $74.6M.

  • 191 institutional investors held Array Biopharma (ARRY) as of Q4 2017, up from 184 in Q3 2017.
  • Funds reported $2.56B of Array Biopharma stock for Q4 2017, up 6.4% quarter-over-quarter.
  • 26 funds opened new Array Biopharma positions in Q4 2017 and 27 closed out, a net change of -1 holder.
  • The largest Array Biopharma buyer in Q4 2017 was BVF Inc, an estimated $26M added.
  • The largest Array Biopharma seller in Q4 2017 was OrbiMed, an estimated $74.6M sold.

Based on aggregated 13F filings for Q4 2017.